Archna Singh, Avijit Mazumder, Saumya Das, A. Kanda, Pankaj Kumar Tyagi, M. Chaitanya
{"title":"Harnessing the Power of Probiotics: Boosting Immunity and Safeguarding against Various Diseases and Infections","authors":"Archna Singh, Avijit Mazumder, Saumya Das, A. Kanda, Pankaj Kumar Tyagi, M. Chaitanya","doi":"10.2174/0127724344308638240530065552","DOIUrl":null,"url":null,"abstract":"\n\nThe human microbiome, a diverse microorganism community, crucially defends\nagainst pathogens. Probiotics, postbiotics, and paraprobiotics alone and in combination are\npotent in countering fungal and waterborne infections, particularly against viral threats.\nThis review focuses on the mechanisms of the microbiome against viral infections, emphasizing\nprobiotic interventions. Certain Lactic Acid Bacteria (LAB) strains effectively eliminate\ntoxic aflatoxin B1 (AFB1) from microfungi-produced mycotoxins. LAB binding to\nAFB1 persists post-gastric digestion, and pre-incubation with mycotoxins reduces probiotic\nadhesion to mucus. Oral probiotic administration in animals increases mycotoxin excretion,\nreducing associated health risks. Bifidobacterium longum and Lactobacillus rhamnosus\nshow exceptional efficacy in removing cyanobacterial toxin microcystin-LR from\ndrinking water. Engineered probiotics promise advanced therapeutic applications for metabolic\ndisorders, Alzheimer's, and type 1 diabetes, serving as diagnostic tools for detecting\npathogens and inflammation markers. In antimicrobial peptide production, genetically\nmodified probiotics producing human β-defensin 2 (HBD2) treat Crohn's disease with implemented\nbiocontainment strategies preventing unintended environmental impacts.\n","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"126 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent advances in anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127724344308638240530065552","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The human microbiome, a diverse microorganism community, crucially defends
against pathogens. Probiotics, postbiotics, and paraprobiotics alone and in combination are
potent in countering fungal and waterborne infections, particularly against viral threats.
This review focuses on the mechanisms of the microbiome against viral infections, emphasizing
probiotic interventions. Certain Lactic Acid Bacteria (LAB) strains effectively eliminate
toxic aflatoxin B1 (AFB1) from microfungi-produced mycotoxins. LAB binding to
AFB1 persists post-gastric digestion, and pre-incubation with mycotoxins reduces probiotic
adhesion to mucus. Oral probiotic administration in animals increases mycotoxin excretion,
reducing associated health risks. Bifidobacterium longum and Lactobacillus rhamnosus
show exceptional efficacy in removing cyanobacterial toxin microcystin-LR from
drinking water. Engineered probiotics promise advanced therapeutic applications for metabolic
disorders, Alzheimer's, and type 1 diabetes, serving as diagnostic tools for detecting
pathogens and inflammation markers. In antimicrobial peptide production, genetically
modified probiotics producing human β-defensin 2 (HBD2) treat Crohn's disease with implemented
biocontainment strategies preventing unintended environmental impacts.